Global ADHD market set to grow at a CAGR of 8% to 2018
The global attention deficit hyperactivity disorder (ADHD) therapeutics market was valued at $3.86 billion in 2010, according to a new report from GlobalData, which forecasts this to expand at a compound annual growth rate (CAGR) of 8.0% over the next eight years, to reach $7.11 billion by 2018.
Between 2005 and 2010 three drugs, namely Daytrana (methylphenidate; originated by Shire but divested to Noven Pharma last summer), Vyvanse (lisdexamfetamine) and Intuniv (guanfacine), both from Shire, were approved in the USA. Vyvanse has a comparatively lesser potential to cause habituation and drug abuse, this has resulted in high acceptance of Vyvanse in the USA despite its high treatment cost in comparison with the existing therapies. In 2009, the authorized generic versions of Shire’s Adderall XR (mixed amphetamine salt) were launched, which resulted in a decline in the US market, in turn triggering a decline in the global ADHD market in 2009.
Geographical variations in growth
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze